TrialESMO open2026

TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancer.

I Schlam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.